泰格医药
(300347)
| 流通市值：305.78亿 | | | 总市值：461.86亿 |
| 流通股本：5.78亿 | | | 总股本：8.72亿 |
| 报告期 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 7,384,039,460.88 | 5,650,477,938.01 | 3,710,850,371.59 | 1,804,571,375.28 |
| 营业收入 | 7,384,039,460.88 | 5,650,477,938.01 | 3,710,850,371.59 | 1,804,571,375.28 |
| 二、营业总成本 | 5,554,124,713.54 | 4,142,186,555.14 | 2,720,025,504.93 | 1,360,291,377.24 |
| 营业成本 | 4,535,510,632.92 | 3,370,920,132.8 | 2,229,763,452.35 | 1,089,048,900.22 |
| 税金及附加 | 27,866,690.14 | 21,435,986.03 | 14,804,829.17 | 6,849,492.11 |
| 销售费用 | 187,314,822.95 | 132,703,603.93 | 88,998,358.31 | 44,911,069.53 |
| 管理费用 | 650,201,401.07 | 527,543,104.76 | 346,470,988.24 | 170,923,614.77 |
| 研发费用 | 261,555,130.31 | 195,343,150.53 | 128,082,457.82 | 64,519,361.97 |
| 财务费用 | -108,323,963.85 | -105,759,422.91 | -88,094,580.96 | -15,961,061.36 |
| 其中:利息费用 | 119,897,366.25 | - | 52,814,698.13 | - |
| 其中:利息收入 | 229,848,679.61 | - | 122,538,479.23 | - |
| 加:公允价值变动收益 | 352,770,634.28 | 710,394,312.74 | 529,757,595.42 | 176,412,728.63 |
| 加:投资收益 | 338,175,307.12 | 127,735,432.89 | 98,902,116.93 | 25,784,682.29 |
| 资产处置收益 | -188,092.67 | 45,215.63 | -5,900.81 | -3,540.15 |
| 资产减值损失(新) | -29,725,239.12 | -11,764,401.66 | -8,218,437.27 | -5,491,837.06 |
| 信用减值损失(新) | -38,372,976.88 | -33,579,759.28 | -21,559,038.29 | -15,237,624.14 |
| 其他收益 | 34,366,177.35 | 10,602,089.43 | 8,896,585.58 | 5,153,375.29 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 2,486,940,557.42 | 2,311,724,272.62 | 1,598,597,788.22 | 630,897,782.9 |
| 加:营业外收入 | 13,453,970.77 | 6,871,087.04 | 4,549,742.46 | 848,031.87 |
| 减:营业外支出 | 11,861,470.03 | 4,125,944.61 | 4,002,437.68 | 683,686.74 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 2,488,533,058.16 | 2,314,469,415.05 | 1,599,145,093 | 631,062,128.03 |
| 减:所得税费用 | 338,606,214.59 | 286,622,443.31 | 191,055,100.26 | 62,736,467.76 |
| 六、净利润 | 2,149,926,843.57 | 2,027,846,971.74 | 1,408,089,992.74 | 568,325,660.27 |
| 持续经营净利润 | 2,149,926,843.57 | 2,027,846,971.74 | 1,408,089,992.74 | 568,325,660.27 |
| 归属于母公司股东的净利润 | 2,024,849,989.11 | 1,879,604,430.16 | 1,388,337,006.2 | 568,455,092.87 |
| 少数股东损益 | 125,076,854.46 | 148,242,541.58 | 19,752,986.54 | -129,432.6 |
| (一)基本每股收益 | 2.34 | 2.17 | 1.61 | 0.66 |
| (二)稀释每股收益 | 2.34 | 2.17 | 1.61 | 0.66 |
| 八、其他综合收益 | 53,516,065.69 | 66,970,735.88 | 103,163,104.24 | -46,553,885.08 |
| 归属于母公司股东的其他综合收益 | 37,983,160.73 | 41,438,207.71 | 69,870,509.83 | -30,860,474.07 |
| 九、综合收益总额 | 2,203,442,909.26 | 2,094,817,707.62 | 1,511,253,096.98 | 521,771,775.19 |
| 归属于母公司股东的综合收益总额 | 2,062,833,149.84 | 1,921,042,637.87 | 1,458,207,516.03 | 537,594,618.8 |
| 归属于少数股东的综合收益总额 | 140,609,759.42 | 173,775,069.75 | 53,045,580.95 | -15,822,843.61 |
| 公告日期 | 2024-03-29 | 2023-10-28 | 2023-08-26 | 2023-04-26 |
| 审计意见(境内) | 标准无保留意见 | | | |